| PET/CT for the staging and follow-up of patients with malignancies. | |
| | |
MedLine Citation:
|
PMID: 19406595 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Positron emission tomography (PET) and computed tomography (CT) complement each other's strengths in integrated PET/CT. PET is a highly sensitive modality to depict the whole-body distribution of positron-emitting biomarkers indicating tumour metabolic activity. However, conventional PET imaging is lacking detailed anatomical information to precisely localise pathologic findings. CT imaging can readily provide the required morphological data. Thus, integrated PET/CT represents an efficient tool for whole-body staging and functional assessment within one examination. Due to developments in system technology PET/CT devices are continually gaining spatial resolution and imaging speed. Whole-body imaging from the head to the upper thighs is accomplished in less than 20 min. Spatial resolution approaches 2-4mm. Most PET/CT studies in oncology are performed with (18)F-labelled fluoro-deoxy-D-glucose (FDG). FDG is a glucose analogue that is taken up and trapped within viable cells. An increased glycolytic activity is a characteristic in many types of cancers resulting in avid accumulation of FDG. These tumours excel as "hot spots" in FDG-PET/CT imaging. FDG-PET/CT proved to be of high diagnostic value in staging and restaging of different malignant diseases, such as colorectal cancer, lung cancer, breast cancer, head and neck cancer, malignant lymphomas, and many more. The standard whole-body coverage simplifies staging and speeds up decision processes to determine appropriate therapeutic strategies. Further development and implementation of new PET-tracers in clinical routine will continually increase the number of PET/CT indications. This promotes PET/CT as the imaging modality of choice for working-up of the most common tumour entities as well as some of the rare malignancies. |
| | |
Authors:
|
T D Poeppel; B J Krause; T A Heusner; C Boy; A Bockisch; G Antoch |
Related Documents
:
|
19695685 - Role of the integrated fdg pet/ct in the surgical management of patients with high risk... 17185195 - The role of integrated computed tomography positron-emission tomography in esophageal c... 19184245 - The early use of pet-ct alters the management of patients with esophageal cancer. 17321235 - The role and clinical value of eus in a multimodality esophageal carcinoma staging prog... 16267665 - Clinical evaluation of bone-subtraction ct angiography (bscta) in head and neck imaging. 15599345 - Comparison of the clinical outcomes of patients having sounds in the temporomandibular ... |
Publication Detail:
|
Type: Journal Article; Review Date: 2009-04-29 |
Journal Detail:
|
Title: European journal of radiology Volume: 70 ISSN: 1872-7727 ISO Abbreviation: Eur J Radiol Publication Date: 2009 Jun |
Date Detail:
|
Created Date: 2009-06-15 Completed Date: 2009-08-26 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8106411 Medline TA: Eur J Radiol Country: Ireland |
Other Details:
|
Languages: eng Pagination: 382-92 Citation Subset: IM |
Affiliation:
|
Department of Nuclear Medicine, University Hospital Essen, Hufelandstr. 55, 45122 Essen, Germany. Thorsten.Poeppel@uni-due.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Fluorodeoxyglucose F18
/
diagnostic use* Follow-Up Studies Humans Neoplasm Staging Neoplasms / diagnosis* Positron-Emission Tomography / methods* Radiopharmaceuticals / diagnostic use Subtraction Technique* Tomography, X-Ray Computed / methods* Whole Body Imaging / methods* |
| Chemical | |
Reg. No./Substance:
|
0/Radiopharmaceuticals; 63503-12-8/Fluorodeoxyglucose F18 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Potential dependent superiority of gold nanoparticles in comparison to iodinated contrast agents.
Next Document: Non-invasive assessment of hepatic fat accumulation in chronic hepatitis C by 1H magnetic resonance ...